Psilocybin and Psilocin
Using fungi to extract the active tryptamines from the biomass to yield psilocybin and psilocin in the form of pure crystalline isolate, salts, tinctures and high bioavailable water-soluble liquids and dry powders. Nirvana plans to sell these products to other researchers under a Dealer’s License from Health Canada.
The extraction of psilocybin and other structurally similar substituted tryptamines from fungi followed by their conversion to the metabolic prodrug 4-POpsilocin. This process is a novel method to yield a new psychoactive substituted tryptamine that has a highly desirable effect. The onset is fairly rapid and the duration is roughly 4 hours.
This novel compound will be ideal for use in a clinical setting due to its short duration and the lack of any apparent body load that’s often associated with psilocybin. We are currently in the finalization phase of the patent process and acquiring this compound for exclusive use in the clinical pharmaceutical market.
Nirvana is also in the process of creating a fully synthetic route to yield psilocybin and psilocin from 4-hydroxytryptophan in large batch quantities. This synthetic psilocybin will be a standardized USP grade pharmaceutical.